Dr. Reddy's Laboratories Ltd.
Snapshot View

4728.25 +57.20 ▲1.2%

30 July 2021, 10:03:00 A.M.
Volume: 15,329

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.drreddys.com
Financial Indicators
Market Cap 77,707.65 Cr.
Earnings per share (EPS) 104.44 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 44.73 Trailing Twelve Months Ending 2021-06
Industry PE 34.39 Trailing Twelve Months Ending 2021-06
Book Value / Share 1,074.71 Trailing Twelve Months Ending 2021-06
Price to Book Value 4.35 Calculated using Price: 4,671.05
Dividend Yield 0.54 Period Ending 2021-03
No. of Shares Subscribed 16.64 Cr. 166,360,134 Shares
FaceValue 5
Company Profile

Dr. Reddy’s Laboratories Limited commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas. The company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and on the New York Stock Exchange in the United States.

Business area of the company

The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations.

Products

  • Generics
  • Over-the-counter
  • APIs (Active Pharmaceutical Ingredients)
  • Biologics
  • Differentiated Formulations

Core Businesses

Pharmaceutical services & active ingredients

  • Global leader in integrated development, manufacturing and supply of APIs.
  • Contract research, development and manufacturing services.

Global Generics

  • Finished dosage businesses in distribution-driven unbranded as well as detailing-driven branded markets.
  • North America, Europe, India, China, Russia & CIS countries are key markets in this segment.

Proprietary Products

  • Developing differentiated formulations that present significantly enhanced benefits in terms of efficacy, ease of use, and the resolution of unmet patient needs.

Awards & Recognitions

  • India’s Best Managed Boards by Mint and Aon Hewitt and by Economic Times and Hays in their respective studies.
  • India’s Best Companies to Work For in the Biotechnology and Pharmaceuticals sector by Great Place To Work Institute.
  • ‘Best Places to Work’ in 2017 in New Jersey by NJBIZ.
  • Global Generics & Biosimilar Award 2018 for CSR initiative of the year
  • India Pharma Corporate Social Responsibility (CSR) programme of the year Award 2018 by Department of Pharmaceuticals, Government of India.
  • Dr. Reddy’s ranked among the top 10 in the Forbes China 2018 list of leading Indian Companies in China.
  • Dr. Reddy’s inclusion in the 2019 Bloomberg Gender-Equality Index.
  • Global Generics & Biosimilars Award 2019: API supplier of the Year at the 6th Annual Global Generics & Biosimilars Awards.
  • Winner of Golden Peacock International Award for Sustainability for the year 2019.

Milestones

  • 1984: The birth of a dream
  • 1991: From molecules to affordable medicines
  • 1995: Expanding to reach patients in other countries
  • 2001: Spreading wings globally
  • 2007: Accelerating access to expensive therapies
  • 2010: From medicines to health
  • 2012: Strengthening capabilities
  • 2014: Re-dedicating to patient-centricity
  • 2015: Dr. Reddy’s Laboratories signs commercialization deal with Hatchtech
  • 2016: Dr. Reddy’s completes acquisition of product portfolio from TEVA
  • 2017: Dr. Reddy's expands commercial operations in Europe
  • 2018: Dr. Reddy's Laboratories announces the launch of Tetrabenazine Tablets in the U.S. Market
  • 2019: Dr. Reddy’s Laboratories enters Nutrition Segment with Celevida in India
  • 2020: Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.22%
1 Week
-12.81%
1 Month
-12.77%
3 Month
-8.44%
6 Month
+2.82%
1 Year
+4.70%
2 Year
+84.55%
5 Year
+60.98%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 27.18 27.88 26.63 18.95 10.20 7.40 14.42 13.38 11.53
Return on Capital Employed (%) 24.79 24.77 22.69 19.55 9.77 8.21 13.41 10.81 15.24
Return on Assets (%) 12.46 13.47 13.67 11.05 6.14 4.23 8.66 8.95 8.01

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 6,369 7,865 9,853 12,570 12,262 12,572 14,024 15,599 17,642
Non Curr. Liab. 1,285 2,182 1,678 877 456 2,538 2,113 -808 -197
Curr. Liab. 5,659 5,790 6,821 6,347 8,420 6,894 5,897 7,214 8,104
Minority Int.
Equity & Liab. 13,313 15,838 18,353 19,794 21,138 22,004 22,034 22,005 25,548
Non Curr. Assets 4,786 5,512 6,476 8,000 11,454 11,505 10,924 9,406 10,998
Curr. Assets 8,527 10,326 11,877 11,794 9,684 10,498 11,110 12,599 14,550
Misc. Exp. not W/O
Total Assets 13,313 15,838 18,353 19,794 21,138 22,004 22,034 22,005 25,548

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 11,896 13,415 15,023 15,568 14,196 14,281 15,448 17,517 19,048
Other Income 150 170 274 295 172 155 338 621 291
Total Income 12,046 13,585 15,297 15,863 14,368 14,436 15,786 18,138 19,339
Total Expenditure -9,176 -10,165 -11,530 -11,983 -11,724 -11,930 -12,270 -15,047 -15,178
PBIDT 2,869 3,421 3,768 3,880 2,644 2,506 3,516 3,091 4,161
Interest -100 -127 -108 -83 -63 -79 -89 -98 -97
Depreciation -550 -648 -760 -939 -1,027 -1,077 -1,135 -1,163 -1,229
Taxation -638 -683 -563 -751 -297 -438 -386 140 -932
Exceptional Items -54
PAT 1,527 1,963 2,336 2,108 1,257 912 1,906 1,970 1,904

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 1,378 1,970 2,524 3,263 2,144 1,803 2,870 2,984 3,570
Cash Fr. Inv. -1,446 -1,694 -2,265 -2,039 -1,840 -1,488 -773 -492 -2,266
Cash Fr. Finan. -157 -24 -433 -1,700 -369 -444 -2,133 -2,516 -30
Net Change -225 251 -174 -477 -65 -129 -35 -24 1,275
Cash & Cash Eqvt 520 862 583 492 378 254 223 196 1,482

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 26.76 26.76 26.76 26.75 26.74 26.74 26.73 26.74 26.73
Public 58.94 59.06 58.93 59.15 59.23 59.16 73.27 60.99 61.18
Depository Receipts 14.30 14.18 14.31 14.10 14.02 14.10 0.00 12.21 12.09
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 28 Jul 2021
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Earnings Call audio recording
Wed, 28 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Financial Results
Wed, 28 Jul 2021
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Outcome of 37th Annual General Meeting & Voting results

Technical Scans View Details

Thu, 29 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 707.25 +0.6%
Divi's Laboratories Ltd. 128,656.69 4,878.00 +0.6%
Cipla Ltd. 71,170.06 881.00 -0.2%
Cadila Healthcare Ltd. 58,547.84 577.60 +1.0%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,072.50 +0.8%
Aurobindo Pharma Ltd. 53,214.94 909.45 +0.1%
Piramal Enterprises Ltd. 52,639.21 2,338.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 707.25 +0.6%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,878.00 +0.6%
Cipla Ltd. Consolidated 2021-03 29.59 881.00 -0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 577.60 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,072.50 +0.8%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 909.45 +0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 39.51 2,338.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 707.25 +0.6%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,878.00 +0.6%
Cipla Ltd. Consolidated 2021-03 3.88 881.00 -0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 577.60 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,072.50 +0.8%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 909.45 +0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.54 2,338.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 707.25 +0.6%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,878.00 +0.6%
Cipla Ltd. Consolidated 2020-03 0.18 881.00 -0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 577.60 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,072.50 +0.8%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 909.45 +0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,338.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 707.25 +0.6%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,878.00 +0.6%
Cipla Ltd. Consolidated 2020-03 10.09 881.00 -0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 577.60 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,072.50 +0.8%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 909.45 +0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,338.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 707.25 +0.6%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,878.00 +0.6%
Cipla Ltd. Consolidated 2020-03 12.53 881.00 -0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 577.60 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,072.50 +0.8%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 909.45 +0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,338.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 707.25 +0.6%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,878.00 +0.6%
Cipla Ltd. Consolidated 2020-03 17,131.99 881.00 -0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 577.60 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,072.50 +0.8%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 909.45 +0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,338.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 707.25 +0.6%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,878.00 +0.6%
Cipla Ltd. Consolidated 2020-03 1,546.98 881.00 -0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 577.60 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,072.50 +0.8%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 909.45 +0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,338.50 +0.9%